Tearsheet

Inovio Pharmaceuticals (INO)

Market Price (11/6/2025): $2.25 | Market Cap: $87.4 Mil
Sector: Health Care | Industry: Biotechnology

Inovio Pharmaceuticals (INO)

Market Price (11/6/2025): $2.25
Market Cap: $87.4 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -41%	Weak multi-year price returns 2Y Excs Rtn is -109%, 3Y Excs Rtn is -167%	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -96 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -52569%
1			Expensive valuation multiples P/SPrice/Sales ratio is 488x
2			Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -69%, Rev Chg QQuarterly Revenue Change % is null
3			Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -51988%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -52037%
4			Valuation getting more expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 72%
5			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -103%

0	Cash is significant % of market cap Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -41%
1	Weak multi-year price returns 2Y Excs Rtn is -109%, 3Y Excs Rtn is -167%
2	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -96 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -52569%
3	Expensive valuation multiples P/SPrice/Sales ratio is 488x
4	Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -69%, Rev Chg QQuarterly Revenue Change % is null
5	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -51988%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -52037%
6	Valuation getting more expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 72%
7	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -103%

Market Valuation & Key Metrics

	11/6/25	2024	2023	2022	2021
Share Price CYE	$2.25	$1.83	$6.12	$18.72	$59.88
Market Cap CYE ($ Mil)	87.4	54.9	139.1	390.9	1,062.6
Total Debt ($ Mil)	10.7	11.9	30.2	32.1	33.0
Total Cash ($ Mil)	47.5	94.1	145.3	253.0	401.3
Enterprise Value ($ Mil)	50.5	66.8	169.3	423.0	1,095.6
Valuation Ratios
P/S TTM	479.1	228.3	163.1	36.3	587.2
P/EBIT TTM	-1.0	-0.5	-1.0	-1.4	-3.5
P/E TTM	-1.0	-0.5	-1.0	-1.3	-3.4
Sector Ratios
P/S TTM (Sector)	3.9	3.5	4.0	4.6	7.3
P/EBIT TTM (Sector)	-1.6	-1.3	-1.3	-1.3	-2.7
P/E TTM (Sector)	-1.8	-1.5	-1.5	-1.3	-2.8

	11/6/25	2024	2023
Share Price CYE	$2.25	$1.83	$6.12
Market Cap CYE ($ Mil)	87.4	54.9	139.1
Total Debt ($ Mil)	10.7	11.9	30.2
Total Cash ($ Mil)	47.5	94.1	145.3
Enterprise Value ($ Mil)	50.5	66.8	169.3
Valuation Ratios
P/S TTM	479.1	228.3	163.1
P/EBIT TTM	-1.0	-0.5	-1.0
P/E TTM	-1.0	-0.5	-1.0
Sector Ratios
P/S TTM (Sector)	3.9	3.5	4.0
P/EBIT TTM (Sector)	-1.6	-1.3	-1.3
P/E TTM (Sector)	-1.8	-1.5	-1.5

	INO	S&P 500
REVENUE GROWTH
Rev LTM ($ Bil)	0.0
Rev Chg Q	-100.0%	6.9%
Rev Chg LTM	-69.2%	5.6%
Rev Chg 3Y Avg	64.0%	5.3%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.1
CFO LTM ($ Bil)	-0.1
Net Inc LTM ($ Bil)	-0.1
Op Mgn LTM	-52,568.6%	18.8%
CFO/Rev LTM	-51,987.6%	20.4%
Net Inc Mgn	-48,131.4%	12.9%
VALUATION	VERY HIGH
P/S	479.2	3.2
P/CFO	-0.9	15.4
P/FCF	-0.9	20.3
P/E	-1.0	23.8
STABILITY	VERY GOOD
Debt/Equity	0.12	0.21
Cash/Assets	0.70	0.07

AI Generated Analysis | Feedback

null

INO Stock

Return (1M):

Factor Drivers of Stock Movement

The 56.8% change in INO stock from 8/6/2025 to 11/5/2025 was primarily driven by a 144.9% change in the company's P/S Multiple.

	8062025	11052025	Change
Stock Price ($)	1.46	2.29	56.85%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	0.28	0.18	-35.59%
P/S Multiple	199.14	487.67	144.89%
Shares Outstanding (Mil)	38.61	38.83	-0.56%
Cumulative Contribution			56.84%

LTM = Last Twelve Months as of date shown

The 30.1% change in INO stock from 5/7/2025 to 11/5/2025 was primarily driven by a 101.2% change in the company's P/S Multiple.

	5072025	11052025	Change
Stock Price ($)	1.76	2.29	30.11%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	0.22	0.18	-16.27%
P/S Multiple	242.41	487.67	101.17%
Shares Outstanding (Mil)	29.99	38.83	-29.47%
Cumulative Contribution			18.82%

LTM = Last Twelve Months as of date shown

The -59.3% change in INO stock from 11/5/2024 to 11/5/2025 was primarily driven by a -69.2% change in the company's Total Revenues ($ Mil).

	11052024	11052025	Change
Stock Price ($)	5.62	2.29	-59.25%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	0.59	0.18	-69.19%
P/S Multiple	258.26	487.67	88.83%
Shares Outstanding (Mil)	27.20	38.83	-42.77%
Cumulative Contribution			-66.71%

LTM = Last Twelve Months as of date shown

The -91.0% change in INO stock from 11/6/2022 to 11/5/2025 was primarily driven by a -98.0% change in the company's Shares Outstanding (Mil).

	11062022	11052025	Change
Stock Price ($)	25.32	2.29	-90.96%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	2.11	0.18	-91.38%
P/S Multiple	234.80	487.67	107.70%
Shares Outstanding (Mil)	19.61	38.83	-98.05%
Cumulative Contribution			-99.65%

LTM = Last Twelve Months as of date shown

Why The Stock Moved

AI Generated Analysis | Feedback

Here are five key points explaining the 61.3% stock movement of Inovio Pharmaceuticals (INO) between July 31, 2025, and November 6, 2025:

1. Positive Second Quarter 2025 Financial Results: Inovio reported a reduced net loss of $23.5 million ($0.61 per share) for Q2 2025, an improvement from $32.2 million in Q2 2024. The company also saw decreased research and development (R&D) and general and administrative (G&A) expenses.

2. Strengthened Cash Position: Inovio's financial standing was bolstered by approximately $22.5 million in net proceeds from a public offering of common stock and warrants in July 2025, with a total cash position of $47.5 million as of June 30, 2025.

3. Significant Clinical Progress for INO-3107: The company announced the successful completion of design verification (DV) testing for its CELLECTRA® 5PSP device, a critical step for the Biologics License Application (BLA) submission for INO-3107. Clinical data for INO-3107 in treating Recurrent Respiratory Papillomatosis (RRP) continued to show strong efficacy, with 86% of patients experiencing a 50-100% reduction in surgeries by Year 2, and 50% achieving a complete response.

4. FDA Agreement on Rolling BLA Submission: The U.S. Food and Drug Administration (FDA) agreed with Inovio's plan for a rolling BLA submission for INO-3107, indicating a streamlined path for regulatory review and the company's projection to finish the submission with an eye towards FDA acceptance by the end of 2025.

5. Completion of Rolling BLA Submission for INO-3107: Inovio completed the rolling submission of its Biologics License Application (BLA) for INO-3107 for the treatment of RRP in adults under the FDA's Accelerated Approval program on November 3, 2025, and requested priority review. This milestone, if granted, could lead to a potential PDUFA (Prescription Drug User Fee Act) date in mid-2026 and would mark INO-3107 as the first DNA medicine approved in the United States.

Show less

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
INO Return	168%	-44%	-69%	-67%	-70%	25%	-94%
Peers Return	-15%	-9%	-6%	-3%	-3%	-17%	-44%
S&P 500 Return	16%	27%	-19%	24%	23%	16%	110%
Monthly Win Rates [3]
INO Win Rate	50%	42%	33%	33%	25%	60%
Peers Win Rate	18%	15%	23%	31%	22%	62%
S&P 500 Win Rate	58%	75%	42%	67%	75%	70%
Max Drawdowns [4]
INO Max Drawdown	-10%	-44%	-72%	-78%	-71%	-28%
Peers Max Drawdown	-20%	-13%	-14%	-15%	-30%	-27%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: VRTX, APM, BBOT, GDTC, HIND. See INO Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 11/5/2025 (YTD)

How Low Can It Go

Unique Key	Event	INO	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-97.9%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	4762.4%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-73.2%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	272.8%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	Not Fully Recovered days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-77.3%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	340.6%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	156 days	120 days
2008 Global Financial Crisis	2008 Global Financial Crisis
2008 Global Financial Crisis% Loss	% Loss	-96.2%	-56.8%
2008 Global Financial Crisis% Gain to Breakeven	% Gain to Breakeven	2506.3%	131.3%
2008 Global Financial CrisisTime to Breakeven	Time to Breakeven	Not Fully Recovered days	1480 days

Compare to VRTX, APM, BBOT, GDTC, HIND

In The Past

Inovio Pharmaceuticals's stock fell -97.9% during the 2022 Inflation Shock from a high on 2/1/2021. A -97.9% loss requires a 4762.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Inovio Pharmaceuticals (INO)

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

null

Better Bets than Inovio Pharmaceuticals (INO)

	INO	Better Performance than INO
Metric	Value	Industry (Biotechnology)
Rev Chg LTM	-69.2%	ABBV (7.4%), AMGN (10.6%), GILD (3.8%), VRTX (10.3%), REGN (2.9%)
Rev Chg 3Y Avg	64.0%	BBIO (727.6%), CYTK (824.6%), AXSM (296.0%), RYTM (136.1%), ARWR (908.8%)
Op Mgn LTM	-52568.6%	ABBV (24.1%), AMGN (24.1%), GILD (37.4%), VRTX (-0.8%), REGN (26.7%)
CFO/Rev LTM	-51987.6%	ABBV (35.0%), AMGN (36.5%), GILD (34.2%), VRTX (31.7%), REGN (35.6%)
FCF/Rev LTM	-52037.1%	ABBV (33.0%), AMGN (32.1%), GILD (32.5%), VRTX (28.5%), REGN (27.2%)
Total Yield	-98.7%	ABBV (3.6%), AMGN (7.0%), GILD (6.7%), VRTX (3.4%), REGN (7.3%)

	INO	Better Performance than INO
Metric	Value	Sector (Health Care)
Rev Chg LTM	-69.2%	LLY (36.8%), JNJ (5.1%), ABBV (7.4%), UNH (10.5%), ABT (6.4%)
Rev Chg 3Y Avg	64.0%	BBIO (727.6%), HIMS (71.0%), CYTK (824.6%), AXSM (296.0%), RYTM (136.1%)
Op Mgn LTM	-52568.6%	LLY (43.0%), JNJ (26.2%), ABBV (24.1%), UNH (6.1%), ABT (17.6%)
CFO/Rev LTM	-51987.6%	LLY (20.5%), JNJ (26.3%), ABBV (35.0%), UNH (4.8%), ABT (20.8%)
FCF/Rev LTM	-52037.1%	LLY (-0.1%), JNJ (20.3%), ABBV (33.0%), UNH (4.0%), ABT (15.8%)
Total Yield	-98.7%	LLY (2.3%), JNJ (8.3%), ABBV (3.6%), UNH (8.6%), ABT (8.3%)

	INO	Better Performance than INO
Metric	Value	All Other Sectors
Rev Chg LTM	-69.2%	NVDA (71.6%), AAPL (6.0%), MSFT (15.6%), GOOGL (13.4%), AMZN (10.9%)
Rev Chg 3Y Avg	64.0%	NVDA (92.0%), APO (129.8%), NU (70.1%), CRDO (74.4%), NBIS (160.6%)
Op Mgn LTM	-52568.6%	NVDA (58.1%), AAPL (31.9%), MSFT (46.3%), GOOGL (32.2%), AMZN (11.4%)
CFO/Rev LTM	-51987.6%	NVDA (46.6%), AAPL (26.6%), MSFT (50.0%), GOOGL (39.3%), AMZN (18.1%)
FCF/Rev LTM	-52037.1%	NVDA (43.6%), AAPL (23.5%), MSFT (26.6%), GOOGL (19.1%), AMZN (2.0%)
Total Yield	-98.7%	NVDA (1.8%), AAPL (2.8%), MSFT (3.4%), GOOGL (3.9%), AMZN (2.7%)

		Best Bets In Health Care Sector
	INO	RPRX	HALO	CPRX	BMY	LNTH	MEDP	PBH	MRK	NBIX	ISRG
What You Pay
P/E	-1.0	22.8	13.4	12.5	15.7	14.5	38.9	13.9	11.1	35.7	71.2
P/EBIT	-1.0	11.0	10.5	10.7	9.5	9.9	33.2	8.9	9.1	26.2	69.5
What You Get
Rev Chg Q	-100.0%	7.9%	22.1%	19.4%	2.8%	-4.1%	23.7%	-6.6%	3.7%	27.8%	22.9%
Rev Chg LTM	-69.2%	3.7%	31.2%	28.5%	1.3%	5.7%	13.9%	0.6%	1.7%	19.6%	22.2%
Rev Chg 3Y Avg	64.0%	1.5%	29.0%	49.9%	1.0%	34.3%	19.9%	0.8%	2.9%	24.6%	16.3%
FCF/Rev 3Y Avg	-24,301.7%	115.2%	45.0%	38.9%	29.0%	26.1%	25.3%	21.6%	22.0%	21.1%	16.5%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic	Date
0	DASHBOARDS
1	Inovio Pharmaceuticals Stock Dropped 5.8% - Have You Assessed the Risk	Return
2	Inovio Pharmaceuticals (INO) Stock: 48% of days in last 3 months had 1% or greater fluctuation
3	Day 5 of Gains Streak for Inovio Pharmaceuticals Stock with 23% Return (vs. 25% YTD) [1/24/2025]	Notification
4	Day 5 of Loss Streak for Inovio Pharmaceuticals Stock with -18% Return (vs. 1.6% YTD) [1/16/2025]	Notification
5	Day 5 of Loss Streak for Inovio Pharmaceuticals Stock with -23% Return (vs. -30% YTD) [11/16/2024]	Notification
6	Inovio Pharmaceuticals vs. S&P500 Correlation	Correlation
7	Inovio Pharmaceuticals Price Volatility	Volatility
8	Day 5 of Gains Streak for Inovio Pharmaceuticals Stock with 17% Return (vs. 2,357% YTD) [3/26/2024]	Notification
9	Inovio Pharmaceuticals Market Price	Market Price
10	Day 5 of Gains Streak for Inovio Pharmaceuticals Stock with 38% Return (vs. -67% YTD) [12/27/2023]	Notification
11	ARTICLES
12	Is A Rise Imminent For Inovio Pharmaceuticals Stock After A Large 17% Fall In A Month		December 16th, 2021
13	Will Inovio Pharmaceuticals Stock See Higher Levels After A 6% Rise In A Week?		October 13th, 2021
14	Down 40% From Recent Highs Can Inovio Pharmaceuticals Stock Rebound?		March 23rd, 2021
15	Can Inovio Pharmaceuticals Stock Recover After The Recent 25% Drop?		March 3rd, 2021
16	Inovio Pharmaceuticals Stock Could See More Downside From $16		September 18th, 2020

	Title
0	DASHBOARDS
1	Inovio Pharmaceuticals Stock Dropped 5.8% - Have You Assessed the Risk
2	Inovio Pharmaceuticals (INO) Stock: 48% of days in last 3 months had 1% or greater fluctuation
3	Day 5 of Gains Streak for Inovio Pharmaceuticals Stock with 23% Return (vs. 25% YTD) [1/24/2025]
4	Day 5 of Loss Streak for Inovio Pharmaceuticals Stock with -18% Return (vs. 1.6% YTD) [1/16/2025]
5	Day 5 of Loss Streak for Inovio Pharmaceuticals Stock with -23% Return (vs. -30% YTD) [11/16/2024]
6	Inovio Pharmaceuticals vs. S&P500 Correlation
7	Inovio Pharmaceuticals Price Volatility
8	Day 5 of Gains Streak for Inovio Pharmaceuticals Stock with 17% Return (vs. 2,357% YTD) [3/26/2024]
9	Inovio Pharmaceuticals Market Price
10	Day 5 of Gains Streak for Inovio Pharmaceuticals Stock with 38% Return (vs. -67% YTD) [12/27/2023]
11	ARTICLES
12	Is A Rise Imminent For Inovio Pharmaceuticals Stock After A Large 17% Fall In A Month
13	Will Inovio Pharmaceuticals Stock See Higher Levels After A 6% Rise In A Week?
14	Down 40% From Recent Highs Can Inovio Pharmaceuticals Stock Rebound?
15	Can Inovio Pharmaceuticals Stock Recover After The Recent 25% Drop?
16	Inovio Pharmaceuticals Stock Could See More Downside From $16

Trade Ideas

Select past ideas related to INO. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
GDRX_10312025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	10312025	GDRX	GoodRx	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	-1.2%	-1.2%	-3.3%
DXCM_10312025_Monopoly_xInd_xCD_Getting_Cheaper	10312025	DXCM	DexCom	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	1.8%	1.8%	0.0%
ACHC_10242025_Dip_Buyer_ValueBuy	10242025	ACHC	Acadia Healthcare	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	-11.6%	-11.6%	-11.7%
PBH_10102025_Dip_Buyer_ValueBuy	10102025	PBH	Prestige Consumer Healthcare	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	-1.9%	-1.9%	-1.9%
REGN_10032025_Dip_Buyer_ValueBuy	10032025	REGN	Regeneron Pharmaceuticals	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	7.4%	7.4%	-7.0%

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
GDRX_10312025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	10312025	GDRX	GoodRx	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	-1.2%	-1.2%	-3.3%
DXCM_10312025_Monopoly_xInd_xCD_Getting_Cheaper	10312025	DXCM	DexCom	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	1.8%	1.8%	0.0%
ACHC_10242025_Dip_Buyer_ValueBuy	10242025	ACHC	Acadia Healthcare	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	-11.6%	-11.6%	-11.7%
PBH_10102025_Dip_Buyer_ValueBuy	10102025	PBH	Prestige Consumer Healthcare	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	-1.9%	-1.9%	-1.9%
REGN_10032025_Dip_Buyer_ValueBuy	10032025	REGN	Regeneron Pharmaceuticals	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	7.4%	7.4%	-7.0%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
SLDP	Solid Power	1.5	51.6%	350.3%
LMND	Lemonade	5.8	34.2%	114.6%
RIGL	Rigel Pharmaceuticals	0.7	33.4%	125.0%
TDC	Teradata	2.6	32.6%	-11.8%
KW	Kennedy-Wilson	1.4	31.2%	2.7%
SEDG	SolarEdge Technologies	2.4	28.9%	201.6%
VCYT	Veracyte	3.6	27.5%	16.3%
AIP	Arteris	0.6	26.1%	52.4%
DAWN	Day One Biopharmaceuticals	0.9	25.2%	-27.9%
ALGT	Allegiant Travel	1.3	25.1%	-22.9%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
BHVN	Biohaven	0.9	-40.2%	-77.7%
TREX	Trex	3.5	-31.1%	-53.0%
SLNO	Soleno Therapeutics	2.4	-26.6%	4.3%
PRGO	Perrigo	2.1	-25.2%	-39.3%
WWW	Wolverine World Wide	1.4	-24.3%	-23.1%
PINS	Pinterest	17.4	-21.8%	-11.2%
ACMR	ACM Research	2.0	-19.9%	106.2%
RPD	Rapid7	0.9	-19.9%	-64.6%
INNV	InnovAge	0.5	-17.6%	1.5%
SUPN	Supernus Pharmaceuticals	2.6	-17.4%	30.3%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TERN	Terns Pharmaceuticals	1.7	126.8%	228.3%
SLDP	Solid Power	1.5	54.2%	350.3%
CSIQ	Canadian Solar	1.7	42.3%	124.8%
CSTL	Castle Biosciences	1.0	41.4%	26.0%
MTSR	Metsera	7.5	36.7%	71379900.0%
GH	Guardant Health	11.8	31.5%	211.1%
KW	Kennedy-Wilson	1.4	31.4%	2.7%
TDC	Teradata	2.6	30.5%	-11.8%
VCYT	Veracyte	3.6	30.0%	16.3%
DAWN	Day One Biopharmaceuticals	0.9	29.8%	-27.9%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
QURE	uniQure	1.4	-63.1%	47.6%
SOC	Sable Offshore	0.5	-57.2%	-75.2%
FMC	FMC	1.7	-54.0%	-71.3%
BHVN	Biohaven	0.9	-53.9%	-77.7%
DD	DuPont de Nemours	16.6	-51.8%	-47.2%
ALVO	Alvotech	1.4	-38.2%	-63.1%
WOLF	Wolfspeed	3.2	-36.7%
SVV	Savers Value Village	1.3	-35.2%	-16.1%
NWL	Newell Brands	1.3	-34.7%	-66.5%
APLS	Apellis Pharmaceuticals	2.5	-33.6%	-37.5%

1 Month Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
PRAX	Praxis Precision Medicines	3.5	216.4%	113.9%
INBX	Inhibrx Biosciences	1.3	145.6%	434.2%
TERN	Terns Pharmaceuticals	1.7	127.7%	228.3%
VTYX	Ventyx Biosciences	0.6	126.1%	311.0%
PUMP	ProPetro	1.1	99.3%	16.2%
VICR	Vicor	4.3	95.1%	96.4%
REPL	Replimune	0.8	84.5%	-29.1%
SNDK	SanDisk	31.4	79.0%
CSIQ	Canadian Solar	1.7	73.3%	124.8%
ATXS	Astria Therapeutics	0.7	68.9%	41.2%

1 Month Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
SOC	Sable Offshore	0.5	-70.6%	-75.2%
FMC	FMC	1.7	-57.1%	-71.3%
QURE	uniQure	1.4	-55.0%	47.6%
DD	DuPont de Nemours	16.6	-49.8%	-47.2%
FI	Fiserv	35.3	-49.5%	-68.8%
LRN	Stride	3.1	-48.6%	-30.8%
ONDS	Ondas	0.9	-45.9%	134.4%
BHVN	Biohaven	0.9	-44.5%	-77.7%
LAC	Lithium Americas	1.0	-44.3%	55.2%
ALVO	Alvotech	1.4	-43.5%	-63.1%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
SLDP	Solid Power	1.5	51.6%	350.3%
LMND	Lemonade	5.8	34.2%	114.6%
RIGL	Rigel Pharmaceuticals	0.7	33.4%	125.0%
TDC	Teradata	2.6	32.6%	-11.8%
KW	Kennedy-Wilson	1.4	31.2%	2.7%
SEDG	SolarEdge Technologies	2.4	28.9%	201.6%
VCYT	Veracyte	3.6	27.5%	16.3%
AIP	Arteris	0.6	26.1%	52.4%
DAWN	Day One Biopharmaceuticals	0.9	25.2%	-27.9%
ALGT	Allegiant Travel	1.3	25.1%	-22.9%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
BHVN	Biohaven	0.9	-40.2%	-77.7%
TREX	Trex	3.5	-31.1%	-53.0%
SLNO	Soleno Therapeutics	2.4	-26.6%	4.3%
PRGO	Perrigo	2.1	-25.2%	-39.3%
WWW	Wolverine World Wide	1.4	-24.3%	-23.1%
PINS	Pinterest	17.4	-21.8%	-11.2%
ACMR	ACM Research	2.0	-19.9%	106.2%
RPD	Rapid7	0.9	-19.9%	-64.6%
INNV	InnovAge	0.5	-17.6%	1.5%
SUPN	Supernus Pharmaceuticals	2.6	-17.4%	30.3%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
TERN	Terns Pharmaceuticals	1.7	126.8%	228.3%
SLDP	Solid Power	1.5	54.2%	350.3%
CSIQ	Canadian Solar	1.7	42.3%	124.8%
CSTL	Castle Biosciences	1.0	41.4%	26.0%
MTSR	Metsera	7.5	36.7%	71379900.0%
GH	Guardant Health	11.8	31.5%	211.1%
KW	Kennedy-Wilson	1.4	31.4%	2.7%
TDC	Teradata	2.6	30.5%	-11.8%
VCYT	Veracyte	3.6	30.0%	16.3%
DAWN	Day One Biopharmaceuticals	0.9	29.8%	-27.9%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
QURE	uniQure	1.4	-63.1%	47.6%
SOC	Sable Offshore	0.5	-57.2%	-75.2%
FMC	FMC	1.7	-54.0%	-71.3%
BHVN	Biohaven	0.9	-53.9%	-77.7%
DD	DuPont de Nemours	16.6	-51.8%	-47.2%
ALVO	Alvotech	1.4	-38.2%	-63.1%
WOLF	Wolfspeed	3.2	-36.7%
SVV	Savers Value Village	1.3	-35.2%	-16.1%
NWL	Newell Brands	1.3	-34.7%	-66.5%
APLS	Apellis Pharmaceuticals	2.5	-33.6%	-37.5%

Peer Comparisons for Inovio Pharmaceuticals

Financials

	INO	VRTX	APM	BBOT	GDTC	HIND	Median
Name	Inovio P.	Vertex P.	Aptorum	BridgeBi.	CytoMed .	Vyome
Mkt Price	2.29	417.00	1.40	12.40	2.11	5.96	4.13
Mkt Cap	0.1	106.6	-	-	-	-	53.3
Rev LTM	0	11,723	-	0	-	-	0
Op Inc LTM	-96	-92	-	-93	-	-	-93
FCF LTM	-95	3,337	-	-60	-	-	-60
FCF 3Y Avg	-127	2,064	-	-	-	-	968
CFO LTM	-95	3,718	-	-60	-	-	-60
CFO 3Y Avg	-127	2,419	-	-	-	-	1,146

Growth & Margins

	INO	VRTX	APM	BBOT	GDTC	HIND	Median
Name	Inovio P.	Vertex P.	Aptorum	BridgeBi.	CytoMed .	Vyome
Rev Chg LTM	-69.2%	10.3%	-	-	-	-	-29.4%
Rev Chg 3Y Avg	64.0%	10.5%	-	-	-	-	37.2%
Rev Chg Q	-100.0%	11.0%	-	-	-	-	-44.5%
QoQ Delta Rev Chg LTM	-35.6%	2.7%	-	-	-	-	-16.5%
Op Mgn LTM	-52,568.6%	-0.8%	-	-	-	-	-26,284.7%
Op Mgn 3Y Avg	-24,717.2%	26.2%	-	-	-	-	-12,345.5%
QoQ Delta Op Mgn LTM	-15,138.5%	1.0%	-	-	-	-	-7,568.7%
CFO/Rev LTM	-51,987.6%	31.7%	-	-	-	-	-25,977.9%
CFO/Rev 3Y Avg	-24,255.8%	23.1%	-	-	-	-	-12,116.4%
FCF/Rev LTM	-52,037.1%	28.5%	-	-	-	-	-26,004.3%
FCF/Rev 3Y Avg	-24,301.7%	19.8%	-	-	-	-	-12,141.0%

Valuation

	INO	VRTX	APM	BBOT	GDTC	HIND	Median
Name	Inovio P.	Vertex P.	Aptorum	BridgeBi.	CytoMed .	Vyome
Mkt Cap	0.1	106.6	-	-	-	-	53.3
P/S	487.7	9.1	-	-	-	-	248.4
P/EBIT	-1.0	23.9	-	-	-	-	11.4
P/E	-1.0	29.0	-	-	-	-	14.0
P/CFO	-0.9	28.7	-	-	-	-	13.9
Total Yield	-98.7%	3.4%	-	-	-	-	-47.6%
Dividend Yield	0.0%	0.0%	-	-	-	-	0.0%
FCF Yield 3Y Avg	-106.1%	2.3%	-	-	-	-	-51.9%
D/E	0.1	0.0	-	-	-	-	0.1
Net D/E	-0.4	-0.0	-	-	-	-	-0.2

Returns

	INO	VRTX	APM	BBOT	GDTC	HIND	Median
Name	Inovio P.	Vertex P.	Aptorum	BridgeBi.	CytoMed .	Vyome
1M Rtn	-5.0%	3.5%	-39.7%	-1.0%	0.0%	13.6%	-0.5%
3M Rtn	56.8%	8.1%	8.5%	-	14.7%	-	11.6%
6M Rtn	30.1%	-4.1%	57.3%	-	-5.6%	-	13.0%
12M Rtn	-59.3%	-16.6%	2.9%	-	-19.6%	-	-18.1%
3Y Rtn	-91.0%	35.0%	-79.0%	-	-	-	-79.0%
1M Excs Rtn	-5.4%	0.4%	-34.2%	0.3%	-3.5%	-5.2%	-4.3%
3M Excs Rtn	51.8%	3.8%	1.3%	-	6.2%	-	5.0%
6M Excs Rtn	9.4%	-24.8%	36.6%	-	-26.3%	-	-7.7%
12M Excs Rtn	-76.6%	-30.1%	-22.3%	-	-27.1%	-	-28.6%
3Y Excs Rtn	-166.7%	-41.9%	-153.5%	-	-	-	-153.5%

Comparison Analyses

	Title
0	GPRO Could Deliver 6.2% Returns And Outperform INO
1	Inovio Pharmaceuticals vs AMC Networks: Similar Market Cap; Which Stock Is A Better Bet?
2	Inovio Pharmaceuticals vs Granite Construction: Similar Market Cap; Which Stock Is A Better Bet?
3	Inovio Pharmaceuticals vs Altimmune: Similar Revenue; Which Stock Is A Better Bet?
4	Inovio Pharmaceuticals vs Astro: Similar Income; Which Stock Is A Better Bet?
5	Inovio Pharmaceuticals vs Sally Beauty: Similar Market Cap; Which Stock Is A Better Bet?

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	6/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	8/12/2025	3/18/2025	3/6/2024	3/1/2023	3/1/2022	3/1/2021	3/12/2020
Key Financials
Total Revenue	0	0	1	10	2	7	4
EBITDA	-85	-104	-130	-271	-297	-150	-107
Operating Income	-96	-112	-133	-268	-301	-124	-111
Net Income	-88	-107	-135	-280	-304	-166	-119
EPS	-2.61	-3.95	-6.09	-14.07	-17.45	-12.84	-14.52
Growth Rates
Total Revenue Growth	-69.2%	-73.8%	-91.9%	478.2%	-76.1%	80.2%	-86.5%
EBITDA Growth	28.2%	20.3%	51.9%	8.7%	-98.3%	-39.3%	-19.5%
Operating Income Growth	18.2%	15.8%	50.1%	11.2%	-142.8%	-11.7%	-18.1%
Net Income Growth	27.9%	20.6%	51.7%	7.9%	-82.5%	-39.4%	-23.1%
Margins
EBITDA Margin	-46471.3%	-47735.2%	-15671.8%	-2639.8%	-16709.7%	-2018.0%	-2610.6%
Operating Income Margin	-52568.6%	-51616.9%	-16036.7%	-2607.4%	-16972.3%	-1674.2%	-2702.1%
Net Income Margin	-48131.4%	-49254.3%	-16239.9%	-2726.7%	-17109.9%	-2245.4%	-2902.8%
Cash & Debt
Total Cash	48	94	145	253	401	412	90
Total Debt	11	12	30	32	33	39	100
Net Debt / (Cash)	-37	-82	-115	-221	-368	-373	10
Cash Flows
Net Cash from Operations	-95	-104	-124	-216	-216	-178	-98
Free Cash from Operations	-95	-105	-125	-217	-217	-179	-99
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3
Period End	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Filing Date	8/12/2025	5/13/2025	3/18/2025	11/14/2024	8/8/2024	5/13/2024	3/6/2024	11/9/2023	8/9/2023	5/10/2023	3/1/2023	11/8/2022
Key Financials Quarterly
Total Revenue	0	0	0	0	0	0	0	0	0	0	0	9
Ebitda	-23	-19	-19	-24	-31	-30	-25	-33	-34	-39	-53	-36
Operating Income	-23	-25	-20	-27	-33	-31	-27	-25	-37	-44	-56	-36
Net Income	-24	-20	-19	-25	-32	-30	-25	-34	-36	-41	-54	-38
EPS	-0.61	-0.51	-0.60	-0.89	-1.19	-1.31	-1.08	-1.52	-1.61	-1.89	-2.55	-1.80
Key Financials TTM
Total Revenue TTM	0	0	0	0	1	1	1	1	10	10	10	11
Ebitda TTM	-85	-93	-104	-110	-118	-121	-130	-159	-162	-235	-271	-323
Operating Income TTM	-96	-106	-112	-119	-117	-121	-133	-162	-173	-240	-268	-317
Net Income TTM	-88	-96	-107	-113	-122	-125	-135	-165	-168	-241	-280	-332
Growth Rates Quarterly
Total Revenue Growth	-100.0%	-	14.0%	-100.0%	-55.4%	-100.0%	-17.7%	-95.8%	-71.2%	-42.3%	-85.1%	3038.2%
EBITDA Growth	27.5%	35.8%	24.2%	25.1%	7.8%	24.6%	53.5%	9.8%	68.1%	47.9%	49.8%	38.3%
Operating Income Growth	30.5%	20.4%	25.6%	-9.2%	10.4%	28.4%	51.0%	30.0%	64.4%	38.7%	47.0%	40.4%
Net Income Growth	27.0%	35.4%	22.5%	25.8%	9.3%	25.0%	54.1%	10.2%	67.2%	48.6%	49.1%	37.2%
Margins Quarterly
EBITDA Margin	-	-29002.7%	-15903.3%	-	-31171.0%	-	-23912.2%	-8388.2%	-15080.5%	-34089.7%	-42354.1%	-394.5%
Operating Income Margin	-	-38337.0%	-17410.8%	-	-32945.9%	-	-26686.3%	-6446.1%	-16392.0%	-38238.2%	-44876.8%	-390.6%
Net Income Margin	-	-30140.5%	-16566.4%	-	-31993.3%	-	-24357.9%	-8734.8%	-15725.3%	-35364.8%	-43687.2%	-412.8%
Cash & Debt
Total Cash	48	68	94	85	110	106	145	167	195	224	253	282
Total Debt	11	11	12	12	13	13	30	30	31	31	32	32
Net Debt / (Cash)	-37	-57	-82	-72	-97	-92	-115	-138	-164	-193	-221	-249
Cash Flows Quarterly
FCF from Operations	-21	-27	-20	-27	-28	-29	-26	-29	-32	-37	-36	-67
Cash Flows TTM
FCF from Operations TTM	-95	-102	-104	-111	-112	-116	-124	-134	-173	-191	-216	-218
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-5.2%	-5.7%	-4.7%	-6.4%	-7.9%	-7.6%	-6.7%	-6.3%	-9.4%	-11.5%	-15.0%	-9.9%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-5.4%	-6.1%	-6.5%	-7.0%	-7.0%	-7.3%	-8.2%	-10.1%	-11.0%	-15.6%	-18.0%	-21.9%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
Development and commercialization of its DNA medicines to help treat and protect people from human	1
Revenue from collaborative arrangements and other contracts		10	2
Other revenue				1	0
Revenue under collaborative research and development arrangements				5	4
Revenue under collaborative research and development arrangements from affiliated entities				1	0
Other revenue from affiliated entities					0
Total	1	10	2	7	4

Price Behavior

Price Behavior

Market Price	$2.29
Market Cap ($ Bil)	0.1
First Trading Date	12/08/1998
Distance from 52W High	-59.6%
	50 Days	200 Days
DMA Price	$2.46	$2.01
DMA Trend	indeterminate	up
Distance from DMA	-6.9%	14.0%
	3M	1YR
Volatility	85.3%	91.0%
Downside Capture	141.71	219.75
Upside Capture	326.56	94.29
Correlation (SPY)	21.1%	26.0%

INO Betas & Captures as of 10/31/2025

	1M	2M	3M	6M	1Y	3Y
Beta	1.89	1.64	1.37	2.68	1.21	1.41
Up Beta	1.39	2.39	0.61	1.54	1.04	1.02
Down Beta	0.53	-0.22	0.28	2.49	0.38	1.14
Up Capture	261%	205%	381%	465%	188%	171%
Bmk +ve Days	14	27	37	74	145	425
Stock +ve Days	10	20	33	66	118	333
Down Capture	315%	298%	100%	307%	157%	111%
Bmk -ve Days	9	17	28	53	106	327
Stock -ve Days	13	23	30	55	120	401

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

1Y 5Y 10Y

Based On 1-Year Data

		Comparison of INO With Other Asset Classes (Last 1Y)
	INO	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-56.6%	0.5%	20.3%	44.6%	1.0%	-2.3%	44.1%
Annualized Volatility	90.6%	17.0%	19.5%	19.9%	16.3%	18.0%	37.0%
Sharpe Ratio	-0.47	-0.14	0.82	1.74	-0.12	-0.28	0.78
Correlation With Other Assets		29.9%	26.0%	5.9%	1.1%	22.1%	10.8%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

		Comparison of INO With Other Asset Classes (Last 5Y)
	INO	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-55.5%	8.9%	17.3%	15.8%	13.5%	7.1%	50.1%
Annualized Volatility	90.0%	14.5%	17.1%	15.6%	18.9%	19.1%	49.2%
Sharpe Ratio	-0.49	0.44	0.83	0.81	0.59	0.28	0.77
Correlation With Other Assets		27.2%	29.5%	9.0%	3.7%	27.9%	16.6%

Based On 10-Year Data

		Comparison of INO With Other Asset Classes (Last 10Y)
	INO	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-29.9%	9.2%	14.4%	12.7%	5.1%	5.1%	78.7%
Annualized Volatility	92.3%	16.7%	18.0%	14.7%	17.7%	20.9%	56.2%
Sharpe Ratio	0.04	0.45	0.69	0.71	0.22	0.21	0.96
Correlation With Other Assets		18.1%	17.3%	8.2%	4.1%	13.3%	7.0%

Short Interest

Short Interest: As Of Date	10152025
Short Interest: Shares Quantity	7,580,599
Short Interest: % Change Since 9302025	-0.6%
Average Daily Volume	1,006,265
Days-to-Cover Short Interest	7.53
Basic Shares Quantity	38,830,053
Short % of Basic Shares	19.5%

Returns Analyses

	Title
0	Inovio Pharmaceuticals Stock Dropped 5.8% - Have You Assessed the Risk
1	Inovio Pharmaceuticals Stock Return Comparison
2	Inovio Pharmaceuticals (INO) Stock Has 47% Chance Of Rise In The Next One Month
3	[10/12/2021] Inovio Pharmaceuticals (INO) Stock Price Forecast: AI Forecasts INO Stock Price To Be Around $7.25 In A Month (Up 4.7%)
4	Inovio Pharmaceuticals Total Shareholder Return (TSR): -68.7% in 2022 and -22.1% 3-yr returns (above peer average)
5	Inovio Pharmaceuticals (INO) Stock Return: AI Predicts INO Average and Excess Return After a Fall or Rise

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
8/12/2025	14.1%	30.2%	77.9%
3/18/2025	-6.7%	-13.8%	-18.1%
11/14/2024	-10.6%	-14.9%	-54.9%
8/8/2024	-3.1%	-10.4%	-26.4%
5/13/2024	0.5%	-2.2%	-16.5%
11/9/2023	-3.7%	13.2%	2.3%
8/9/2023	12.9%	8.2%	11.9%
5/10/2023	-3.1%	-11.0%	-35.4%
...
SUMMARY STATS
# Positive	6	6	5
# Negative	8	8	9
Median Positive	8.9%	22.7%	11.9%
Median Negative	-6.5%	-12.4%	-33.7%
Max Positive	23.8%	30.2%	77.9%
Max Negative	-30.2%	-48.9%	-54.9%

	Forward Returns
8/12/2025	14.1%	30.2%	77.9%
3/18/2025	-6.7%	-13.8%	-18.1%
11/14/2024	-10.6%	-14.9%	-54.9%
8/8/2024	-3.1%	-10.4%	-26.4%
5/13/2024	0.5%	-2.2%	-16.5%
11/9/2023	-3.7%	13.2%	2.3%
8/9/2023	12.9%	8.2%	11.9%
5/10/2023	-3.1%	-11.0%	-35.4%
3/1/2023	4.8%	-4.0%	-36.1%
11/8/2022	1.9%	16.8%	-14.0%
8/9/2022	23.8%	29.0%	2.9%
5/10/2022	-27.3%	-20.1%	-33.7%
1/20/2021	-6.4%	28.6%	42.4%
3/9/2020	-30.2%	-48.9%	-40.1%
SUMMARY STATS
# Positive	6	6	5
# Negative	8	8	9
Median Positive	8.9%	22.7%	11.9%
Median Negative	-6.5%	-12.4%	-33.7%
Max Positive	23.8%	30.2%	77.9%
Max Negative	-30.2%	-48.9%	-54.9%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
6302025	8122025	10-Q 6/30/2025
3312025	5132025	10-Q 3/31/2025
12312024	3182025	10-K 12/31/2024
9302024	11142024	10-Q 9/30/2024
6302024	8082024	10-Q 6/30/2024
3312024	5132024	10-Q 3/31/2024
12312023	3062024	10-K 12/31/2023
9302023	11092023	10-Q 9/30/2023
6302023	8092023	10-Q 6/30/2023
3312023	5102023	10-Q 3/31/2023
12312022	3012023	10-K 12/31/2022
9302022	11082022	10-Q 9/30/2022
6302022	8092022	10-Q 6/30/2022
3312022	5102022	10-Q 3/31/2022
12312021	3012022	10-K 12/31/2021
9302021	11092021	10-Q 9/30/2021

Insider Activity

Expand for More

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Inovio Pharmaceuticals (INO)

Market Price (11/6/2025): $2.25 | Market Cap: $87.4 MilSector: Health Care | Industry: Biotechnology

Inovio Pharmaceuticals (INO)

Market Price (11/6/2025): $2.25Market Cap: $87.4 MilSector: Health CareIndustry: Biotechnology

Market Valuation & Key Metrics

INO Stock

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Inovio Pharmaceuticals (INO)

Interactive Breakdown

Better Bets than Inovio Pharmaceuticals (INO)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Inovio Pharmaceuticals

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (11/6/2025): $2.25 | Market Cap: $87.4 Mil
Sector: Health Care | Industry: Biotechnology

Market Price (11/6/2025): $2.25
Market Cap: $87.4 Mil
Sector: Health Care
Industry: Biotechnology